Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress

Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industry Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic eligible to receive a share of profits from product sales Expanded strategic collaboration with Fermbox Bio, including the launch of animal-origin-free recombinant DNase I (RNase-free) as the first commercialized product under the expanded partnership, while advancing scale-up and commercialization activities for additional recombinant products, including transferrin Signed an OEM distribution agreement with IBT Bioservices to commercialize Dyadic's recombinant products, with initial product quantities completed for shipment to support commercialization through IBT's global distribution channels Entered a development and commercialization agreement with BRIG Bio to produce animal-free bovine alpha-lactalbumin for global nutrition markets, which includes funded development, milestones, and potential revenue participation Continued advancement of Gates Foundation-supported RSV and malaria antibody programs and the CEPI/FBS H5 avian influenza program, leveraging AI-enabled target development and generating additional validation of Dyadic's C1 platform Cash, cash equivalents, restricted cash and investment grade securities of approximately $6.6 million as of March 31, 2026 Dyadic to host an earnings call today at 5:00 pm ET JUPITER, Fla., May 13, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today reported its financial results for Q1 2026 along with significant corporate achievements.